NeurologyLive® Friday 5 — December 15, 2023

News
Article

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending December 15, 2023.

Welcome to NeurologyLive®'s Friday 5! Every week, the staff compiles 5 highlights of NeurologyLive®'s widespread coverage in neurology, ranging from newsworthy study findings and FDA action to expert interviews and peer-to-peer panel discussions.

1: Stigma in Epilepsy in 2023: How Far Have We Come?

In recent conversations with experts in epilepsy, the impact of stigmatization remains high for patients and ongoing efforts by clinicians to address this issue in the clinical setting has been underscored, despite the global lack of awareness about new treatments and other resources.

Stigma in Epilepsy in 2023: How Far Have We Come?

2: IJMSC Insights: Drs Rainka, Aladeen, and Mattle on Medical Cannabis and MS

A new feature on NeurologyLive®, IJMSC Insights offers a closer look at the latest research and the people behind it from the community of the International Journal of Multiple Sclerosis Care (IJMSC) and the Consortium of Multiple Sclerosis Centers (CMSC).

IJMSC Insights: Drs Rainka, Aladeen, and Mattle on Medical Cannabis and MS

3: NeuroVoices: Irfan Qureshi, MD, on the Therapeutic Potential of Antiseizure Agent BHV-7000

In this edition of NeuroVoices, the chief medical officer of Biohaven discussed early-stage data supporting the efficacy and safety of BHV-7000, a selective Kv7.2/7.3 potassium channel activator in development for patients with epilepsy.

NeuroVoices: Irfan Qureshi, MD, on the Therapeutic Potential of Antiseizure Agent BHV-7000

4: Gaining Greater Insights Into Tuberous Sclerosis Complex-Associated Neuropsychiatric Disorders: Elizabeth M. Cassidy, MPH

The research project manager at the TSC Alliance provided additional clarity into a new study presented at AES 2023 assessing the links between TSC-associated neuropsychiatric disorders and seizure duration. [WATCH TIME: 4 minutes]

Gaining Greater Insights Into Tuberous Sclerosis Complex-Associated Neuropsychiatric Disorders: Elizabeth M. Cassidy, MPH

5: Growing Trofinetide’s Long-Term Profile as First Approved Rett Syndrome Therapy: Ponni Subbiah, MD, MPH

The senior vice president, global head of medical affairs, and chief medical officer at Acadia Pharmaceutical, provided an overview of LILAC-2, a long-term, open-label study assessing the treatment benefits of trofinetide (Daybue). [WATCH TIME: 6 minutes]

 Growing Trofinetide’s Long-Term Profile as First Approved Rett Syndrome Therapy: Ponni Subbiah, MD, MPH
Recent Videos
Clifford R. Jack Jr., MD
David T. Jones, MD
Clifford R. Jack Jr., MD
 Lisa Mosconi, PhD
Emma Ciafaloni, MD, an expert on Duchenne muscular dystrophy
 Justin Davanzo, MD
1 KOL is featured in this series.
Aliza Ben-Zacharia, PhD, DNP, ANP-BC, FAAN
© 2024 MJH Life Sciences

All rights reserved.